OTTMUSG00000017976 Inhibitors
Melanoma antigen, family B, 5-like is a protein whose functional activity is contingent on specific signaling pathways within the cell. The first pathway to consider is the protein kinase C (PKC) pathway, where Staurosporine, a potent PKC inhibitor, plays a crucial role. By inhibiting PKC, Staurosporine disrupts downstream signaling processes essential for the functional expression of melanoma antigen, family B, 5-like. This leads to a reduction in the protein's activity as the critical signaling cascades are interrupted. Similarly, the PI3K/Akt and mTOR pathways are vital for cell survival and proliferation, where LY294002 and Rapamycin come into play, respectively. LY294002, a PI3K inhibitor, and Rapamycin, an mTOR inhibitor, both lead to a disturbed cellular environment that is necessary for melanoma antigen, family B, 5-like's functional activity. The disruption of these pathways results in the inhibition of the protein's function, as the signaling environment it relies on is altered.
Additionally, the MAPK/ERK pathway, where MEK1/2 are key components, is crucial for the functional activity of melanoma antigen, family B, 5-like. Inhibitors like U0126, PD98059, LY3214996, and AZD6244 specifically target components of this pathway. U0126 and PD98059 are MEK inhibitors, while LY3214996 and AZD6244 target ERK and MEK1/2, respectively. The inhibition of these components results in the hindrance of the signaling required for the protein's activity, leading to its functional inhibition. In parallel, other inhibitors such as SP600125 and SB203580 target the stress-activated protein kinase (JNK) and p38 MAPK, respectively. These pathways are involved in stress response and inflammatory signaling, which melanoma antigen, family B, 5-like may participate in. By inhibiting these pathways, SP600125 and SB203580 contribute to the decrease in the functional activity of melanoma antigen, family B, 5-like. Lastly, Dasatinib and Triciribine, by inhibiting broad-spectrum tyrosine kinases and Akt specifically, disrupt various signaling pathways, further contributing to the inhibition of melanoma antigen, family B, 5-like by altering the signaling environment essential for its function. These chemicals collectively represent a comprehensive approach to inhibiting the functional activity of melanoma antigen, family B, 5-like by targeting the essential signaling pathways it depends on.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits protein kinase C (PKC), a regulator in the pathway melanoma antigen, family B, 5-like is involved in. Inhibiting PKC can lead to reduced activity of melanoma antigen, family B, 5-like by disrupting downstream signaling processes that are crucial for its functional expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin acts on the mTOR pathway, a key regulator of cell growth and proliferation. The inhibition of mTOR can disrupt the cellular environment that melanoma antigen, family B, 5-like needs for its functional activity, leading to its inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. Since PI3K/Akt signaling is important for cell survival and proliferation, inhibiting this pathway can lead to the functional inhibition of melanoma antigen, family B, 5-like by disrupting the signaling environment it relies on. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, key components in the MAPK/ERK pathway. By inhibiting this pathway, U0126 can hinder the signaling required for the functional activity of melanoma antigen, family B, 5-like, leading to its inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor, which can prevent the activation of the MAPK/ERK pathway. Inhibition of this pathway disrupts the signaling that melanoma antigen, family B, 5-like depends on for its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 inhibits JNK, which is part of the stress-activated protein kinase pathway. By inhibiting JNK, SP600125 can decrease the functional activity of melanoma antigen, family B, 5-like by affecting stress response signaling pathways it may be involved in. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The inhibition of p38 MAPK can lead to the reduction in the functional activity of melanoma antigen, family B, 5-like by altering the inflammatory response signaling pathways it participates in. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, it disrupts the PI3K/Akt signaling pathway, crucial for cell survival and proliferation, thereby potentially inhibiting the activity of melanoma antigen, family B, 5-like. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor. By inhibiting tyrosine kinases, it can disrupt various signaling pathways, potentially leading to the inhibition of melanoma antigen, family B, 5-like by altering its signaling environment. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits Akt, a key component in the PI3K/Akt pathway. By inhibiting Akt, it can reduce the activity of melanoma antigen, family B, 5-like by disrupting the signaling pathways necessary for its function. | ||||||